open access
The influence of g-linolenic acid and honokiol on skin functions
open access
Abstract
The diet and related supply of unsaturated fatty acids play an important role in the pathogenesis of diet-related disorders. γ-linolenic acid (GLA) is an omega-6 polyunsaturated fatty acid that has important biological functions in the human body, being an indispensable substrate for the production of eicosanoids. It is also one of the components of cell membranes, which is additionally involved in the processes of cholesterol transport and oxidation. The results of recent studies on the beneficial effects of GLA supplementation are very promising, including dermatological diseases. They support the hypothesis that GLA is an essential fatty acid for the normal function of the skin, which itself is unable to synthesise it. GLA deficiencies were found in many chronic skin diseases, such as: atopic dermatitis, psoriasis and eczema. Therefore, the preservation of the optimal structure and function of the skin largely depends on the exogenously supplied GLA. The rich source of this acid are vegetable oils commonly used in folk medicine. In addition, honokiol traditionally used in eastern medicine has a pleiotropic effect also in chronic dermatological diseases, not only because of its anti-inflammatory or antioxidant properties, but also because of its neuroprotective effect. Honokiol, by mild anxiolytic and antidepressant effects, improves the mood and increases the quality of life in patients with dermatological problems.
Abstract
The diet and related supply of unsaturated fatty acids play an important role in the pathogenesis of diet-related disorders. γ-linolenic acid (GLA) is an omega-6 polyunsaturated fatty acid that has important biological functions in the human body, being an indispensable substrate for the production of eicosanoids. It is also one of the components of cell membranes, which is additionally involved in the processes of cholesterol transport and oxidation. The results of recent studies on the beneficial effects of GLA supplementation are very promising, including dermatological diseases. They support the hypothesis that GLA is an essential fatty acid for the normal function of the skin, which itself is unable to synthesise it. GLA deficiencies were found in many chronic skin diseases, such as: atopic dermatitis, psoriasis and eczema. Therefore, the preservation of the optimal structure and function of the skin largely depends on the exogenously supplied GLA. The rich source of this acid are vegetable oils commonly used in folk medicine. In addition, honokiol traditionally used in eastern medicine has a pleiotropic effect also in chronic dermatological diseases, not only because of its anti-inflammatory or antioxidant properties, but also because of its neuroprotective effect. Honokiol, by mild anxiolytic and antidepressant effects, improves the mood and increases the quality of life in patients with dermatological problems.
Keywords
honokiol, γ-Linolenic acid, skin diseases
About this articleTitle
The influence of g-linolenic acid and honokiol on skin functions
Journal
Issue
Article type
Review paper
Pages
152-156
Published online
2018-03-02
Page views
1722
Article views/downloads
5612
Bibliographic record
Forum Dermatologicum 2017;3(4):152-156.
Keywords
honokiol
γ-Linolenic acid
skin diseases
Authors
Aleksandra Lesiak
Magdalena Ciążyńska
References (30)- Kapoor R. Gamma Linolenic Acid: A Natural Anit-inflammatory Agent – Part 1. Natural Pharmacy. 2006.
- Shen JL, Man KM, Huang PH, et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010; 15(9): 6452–6465.
- Calder P. n-3 Polyunsaturated Fatty Acids and Cytokine Production in Health and Disease. Annals of Nutrition and Metabolism. 1997; 41(4): 203–234.
- Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr. 2000; 71(1 Suppl): 171S–5S.
- Hornych A, Oravec S, Girault F, et al. The effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandin synthesis in older subjects. Bratisl Lek Listy. 2002; 103(3): 101–107.
- Muggli R. Systemic evening primrose oil improves the biophysical skin parameters of healthy adults. Int J Cosmet Sci. 2005; 27(4): 243–249.
- Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol. 2003; 21(2): 109–115.
- Van GCJ, Thijs C, Henquet CJ, et al. γ-Linolenic acid supplementation for prophylaxis of atopic dermatitis – a randomized controlled trail in infants at high familial risk. Am J Clin Nutr. 2003; 77: 943–951.
- Lamer-Zarawska E. Olej wiesiołkowy w profilaktyce, terapii i kosmetyce. W: Zbiór prac II sympozjum n.t. Olej z nasion wiesiołka w profilaktyce i terapii. MakoLab, Łód. ; 1995: 35–51.
- Stawczyk M, Szczerkowska-Dobosz A. The role of nutrition in psoriasis — a chronic inflammatory systemic disease. Via Medica, 2011 : 205–212.
- Yaqoob P. Fatty acids as gatekeepers of immune cell regulation. Trends Immunol. 2003; 24(12): 639–645.
- Yu YM, Chan YH, Calder PC, et al. GUSTO study group. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006; 83(6 Suppl): 1505S–1519S.
- Bittiner SB, Tucker WF, Cartwright I, et al. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet. 1988; 1(8582): 378–380.
- Grupa AK. Ellis C.N, Tellner D.C., Anderson T.F., Voorhees J.J.: Double blind, randomized, placebo-controlled study to evauate the efficiency of fish oil and low-dose UVB in the treatment of psoriasis. Br J Dermatol. 1989; 120: 801–807.
- Mayser P, Morowietz U, Arenberger P, et al. in: Omega-3 fatty acid – based lipid infusion in patients with chronic plaque psoriasis: results of a double blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1988; 38: 539–547.
- Domínguez F, Chivez M, Garduñ-Ramírez ML, et al. Production of honokiol and magnolol in suspension cultures of Magnolia dealbata Zucc. Nat Prod Commun. 2009; 4(7): 939–943.
- Maruyama Y, Kuribara H. Overview of the Pharmacological Features of Honokiol. CNS Drug Reviews. 2006; 6(1): 35–44.
- Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 2000; 7(2): 249–271.
- Lee YJ, Lee YMo, Lee CK, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011; 130(2): 157–176.
- Woodbury A, Yu SP, Wei L, et al. Neuro-modulating effects of honokiol: a review. Front Neurol. 2013; 4: 130.
- Fried LE, Arbister JL. Multifunctional Antiangiogenic and Antitumor Agent, Antioxidants & Redox Signaling. 2009; 11(5): 1139–47.
- Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res. 2010; 302(2): 71–83.
- Chilampalli, S.; Zhang, X.; Fahmy, H.; Kaushik, R. S.; Zeman, D.; Hildreth, M. B.; Dwivedi, C. Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res. 2010; 30(3): 777–783.
- Bang KH, Kim YK, Min BS, et al. Antifungal activity of magnolol and honokiol. Arch Pharm Res. 2000; 23(1): 46–49.
- Clark AM, El-Feraly FS, Li WS. Antimicrobial activity of phenolic constituents of Magnolia grandiflora L. J Pharm Sci. 1981; 70(8): 951–952.
- Bae EA, Han MJ, Kim NJ, et al. Anti-Helicobacter pylori activity of herbal medicines. Biol Pharm Bull. 1998; 21(9): 990–992.
- Park J, Lee J, Jung E, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol. 2004; 496(1-3): 189–195.
- Lee J, Jung E, Park J, et al. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med. 2005; 71(4): 338–343.
- Dikalov S, Losik T, Arbiser JL. Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol. 2008; 76(5): 589–596.
- Kuribara H, Stavinoha WB, Maruyama Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. J Pharm Pharmacol. 1998; 50(7): 819–826.
